[Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].
Stamminger
T
T
Institut für Klinische u. Molekulare Virologie der Univ., Erlangen.
Fleckenstein
B
B
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D016049:Didanosine / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017245:Foscarnet / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use*
D017245:Foscarnet; D015215:Zidovudine; D016049:Didanosine
Aktuelle Entwicklungen der antiviralen Chemotherapie. Folge 4 (Schluss): Foscarnet, Zidovudin, Didanosin.